SUMO2 is shown to protect FASN, where the combination of the protein synthesis inhibitor (cycloheximide) or proteasomal degradation inhibitor (MG132) with SUMO2 silencing, delays FASN degradation in breast cancer cell lines. The gene discussed is SUMO2; the disease is breast carcinoma.